Our results reveal that the constant lipid profile characterizing the CeD group is evident long before (years) the CeD clinical manifestations or even the production of the specific anti-TG2 antibodies in very healthy and thriving infants at 4 months and is, thus, unlikely to be linked to an inflammation state. Here, TGM2 is linked to cranioectodermal dysplasia.